Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia

1 Jan 2017

Abstract excerpt

OBJECTIVE: To elucidate the degree of genetic polymorphisms CYP2C19 (CYP2C19*2, CYP2C19*3) of key drug metabolizing enzymes on the antiplatelet effect of clopidogrel response in patients with acute ischemic stroke from Saudi Arabia. METHODS: A case-control study carried out at Neurology Clinics at Asser Central Hospital, Abha, Kingdom of Saudi Arabia from October 2015 to January 2016 and included 25 stroke...

Topics

Join the communities discussing this publication.

Acute Ischemic Stroke Management
Antiplatelet Therapy and Cardiovascular Diseases
Platelet Disorders and Treatments

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28064328
DOI: 10.17712/nsj.2017.1.20160303

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi ArabiaPMID 28064328Read ↗

CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.Semantic proximity Read ↗

Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.Semantic proximity Read ↗

The effect of the CYP 2C19*2 polymorphism on stroke care.Semantic proximity Read ↗

Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.Semantic proximity Read ↗

Prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup.Semantic proximity Read ↗

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.Semantic proximity Read ↗

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives.Semantic proximity Read ↗

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Genetic variability in stroke patients: CYP2C19 polymorphisms unraveled.Semantic proximity Read ↗

Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant.Semantic proximity Read ↗

Cytochrome P-450 CYP2C19 genetic polymorphism and its relation with clopidogrel resistance.Semantic proximity Read ↗

Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.